<DOC>
	<DOC>NCT02256852</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability, compliance and mechanism of action of study drug (QBKPN SSI) in subjects with two or more second primary pre-invasive or invasive adenocarcinoma following surgical section of Stage 1 NSCLC.</brief_summary>
	<brief_title>Exploratory Study of QBKPN SSI in Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Please refer to summary above.</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>Male or female who is at or above the age of consent Histologically confirmed original diagnosis of lung cancer Life expectancy greater than 12 months ECOG performance status 0, 1, or 2 at screening Female subjects who agree to practice two effective methods of contraception from the time of signing the informed consent form through one month after the last dose of study drug Male subjects who agree to practice effective barrier contraception during the entire study drug period and through one month after the last dose of study drug Extrathoracic lung cancer progression Any active malignancies Any uncontrolled or major organ dysfunction Any past or current radiation or systemic therapies for the treatment of lung cancer Known HIV infection or other immunosuppressive disorder Concurrently participating in another study with an investigational immunotherapy or have received investigational immunotherapy within 3 months prior to screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>